Presymptomatic compensation in Parkinson's disease is not dopamine-mediated

This publication has 57 references indexed in Scilit:

• Parkinsonʼs disease: imaging update
  Current Opinion in Neurology, 2002
• Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys
  Neurobiology of Disease, 2001
• Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson’s disease
  The FASEB Journal, 2001
• The Frontal Cortex-Basal Ganglia System in Primates
  Critical Reviews™ in Neurobiology, 1996
• Effects of Nigrostriatal Denervation and L‐Dopa Therapy on the GABAergic Neurons of the Striatum in MPTP‐treated Monkeys and Parkinson's Disease: An In Situ Hybridization Study of GAD₆₇ mRNA
  European Journal of Neuroscience, 1995
• Clinical observations on the rate of progression of idiopathic parkinsonism
  Brain, 1994
• Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons
  Annals of Neurology, 1994
• A 2-DEOXYGLUCOSE STUDY OF THE EFFECTS OF DOPAMINE AGONISTS ON THE PARKINSONIAN PRIMATE BRAIN
  Brain, 1992
• Differentiation of Dopamine Overflow and Uptake Processes in the Extracellular Fluid of the Rat Caudate Nucleus with Fast‐Scan In Vivo Voltammetry
  Journal of Neurochemistry, 1988
• Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake
  Neuroscience Letters, 1986